382P Beyond pathologic response: Does spontaneous tumor regression (STR) influence outcomes in resected stage IIIA-N2 non-small cell lung cancer (NSCLC)? A LungART trial substudy
In the chemoimmunotherapy era, pathological response to neoadjuvant treatment (NA) has arisen as a surrogate endpoint for survival in resectable NSCLC. However, the prognostic value of STR - described in untreated patients (pts) across multiple tumor types - remains unaddressed. We assessed the impact of viable tumor fraction (VTF) as a marker of STR in resected stage IIIA-N2 NSCLC.
Authors
- V.M. Albarran Artahona
- JP. Dales
- E. Bouvier
- C. Le Pechoux
- M. Guckenberger
- F. Morin
- R. Reyes
- M.R. Ghigna
- V. Westeel
- B. Besse
- J. Remon Masip
- J. Adam
- A. Levy
- C. Faivre-Finn
- A. Lopez Gutierrez
- D. Diaz-Jimenez
- G. Granier
- N. Cozic
- W.S. Zrafi
Institutions
- Inserm (FR)
- Institut Gustave Roussy (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Instituto Oncológico Dr. Rosell (ES)
- Intergroupe Francophone de Cancérologie Thoracique (FR)
- University Hospital of Zurich (CH)
- Hôpital Nord (FR)
- The Christie NHS Foundation Trust (GB)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2025.101568
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00